-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind reports successful formulation study for intranasal MEAI delivery in alcohol use disorder program

PUBT·07/07/2026 20:02:29
Listen to the news
Clearmind reports successful formulation study for intranasal MEAI delivery in alcohol use disorder program
  • Clearmind disclosed successful formulation-feasibility results for intranasal delivery of its lead candidate MEAI, supporting a potential new administration route.
  • The work produced a stable, fully soluble intranasal solution, clearing an early development step toward optimization.
  • The intranasal program is initially aimed at alcohol use disorder, targeting improved convenience and potential performance versus existing delivery approaches.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-075933), on July 07, 2026, and is solely responsible for the information contained therein.